Becton, Dickinson and Company is involved in a stockholder derivative litigation concerning allegations against its officers and directors. The claims suggest that the individual defendants did not fulfill their fiduciary duties by making false and misleading statements regarding the Alaris infusion pump system between November 5, 2019, and February 5, 2020. A proposed settlement has been reached, and if approved by the court, current BD stockholders will be barred from contesting the approval. This settlement follows mediation in a related federal securities class action, with a hearing initially set for August 2023, which was adjourned for mediation. The proceedings are taking place in the U.S. District Court for the District of New Jersey.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。